Cargando…

Analysis of mutational and clinicopathologic characteristics of lung adenocarcinoma with clear cell component

INTRODUCTION: Lung adenocarcinoma with clear cell component is extremely rare and the cases reported in literature remain scarce. The biological behaviors, clinicopathologic characteristics, mutational status and prognosis of lung adenocarcinoma with clear cell component are still uncertain. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Chang, Pan, Xufeng, Wang, Rui, Li, Yuan, Shen, Xuxia, Shi, Jianxin, Chen, Haiquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029726/
https://www.ncbi.nlm.nih.gov/pubmed/27013585
http://dx.doi.org/10.18632/oncotarget.8258
_version_ 1782454567131152384
author Gu, Chang
Pan, Xufeng
Wang, Rui
Li, Yuan
Shen, Xuxia
Shi, Jianxin
Chen, Haiquan
author_facet Gu, Chang
Pan, Xufeng
Wang, Rui
Li, Yuan
Shen, Xuxia
Shi, Jianxin
Chen, Haiquan
author_sort Gu, Chang
collection PubMed
description INTRODUCTION: Lung adenocarcinoma with clear cell component is extremely rare and the cases reported in literature remain scarce. The biological behaviors, clinicopathologic characteristics, mutational status and prognosis of lung adenocarcinoma with clear cell component are still uncertain. METHODS: Thirty-eight lung adenocarcinomas with clear cell component and 1659 lung adenocarcinomas were subjected to the study. All the corresponding clinicopathologic data, the distributions of relapse-free survival (RFS) and overall survival (OS), and the status of gene mutations were investigated. RESULTS: Of 1697 adenocarcinomas, 38 (2.2%) had clear cell component. Fifty percent of adenocarcinomas with clear cell component (11/22) harbored EGFR mutation, 41 percent (9/22) harbored KRAS mutation and 5 percent (1/22) harbored AKT1 mutation. Univariable analysis revealed that sex, age, tumor stage, tumor size, nodal stage and pathology were all significant predictors of RFS and OS while the tumor size and nodal stage were still significant predictors in multivariable analysis. There were significantly differences in RFS and OS for lung adenocarcinomas with clear cell component compared with those lung adenocarcinomas. CONCLUSIONS: Lung adenocarcinoma with clear cell component is a rare, malignant tumor with poor prognosis and displays more frequent EGFR and KRAS mutations.
format Online
Article
Text
id pubmed-5029726
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-50297262016-09-29 Analysis of mutational and clinicopathologic characteristics of lung adenocarcinoma with clear cell component Gu, Chang Pan, Xufeng Wang, Rui Li, Yuan Shen, Xuxia Shi, Jianxin Chen, Haiquan Oncotarget Research Paper INTRODUCTION: Lung adenocarcinoma with clear cell component is extremely rare and the cases reported in literature remain scarce. The biological behaviors, clinicopathologic characteristics, mutational status and prognosis of lung adenocarcinoma with clear cell component are still uncertain. METHODS: Thirty-eight lung adenocarcinomas with clear cell component and 1659 lung adenocarcinomas were subjected to the study. All the corresponding clinicopathologic data, the distributions of relapse-free survival (RFS) and overall survival (OS), and the status of gene mutations were investigated. RESULTS: Of 1697 adenocarcinomas, 38 (2.2%) had clear cell component. Fifty percent of adenocarcinomas with clear cell component (11/22) harbored EGFR mutation, 41 percent (9/22) harbored KRAS mutation and 5 percent (1/22) harbored AKT1 mutation. Univariable analysis revealed that sex, age, tumor stage, tumor size, nodal stage and pathology were all significant predictors of RFS and OS while the tumor size and nodal stage were still significant predictors in multivariable analysis. There were significantly differences in RFS and OS for lung adenocarcinomas with clear cell component compared with those lung adenocarcinomas. CONCLUSIONS: Lung adenocarcinoma with clear cell component is a rare, malignant tumor with poor prognosis and displays more frequent EGFR and KRAS mutations. Impact Journals LLC 2016-03-22 /pmc/articles/PMC5029726/ /pubmed/27013585 http://dx.doi.org/10.18632/oncotarget.8258 Text en Copyright: © 2016 Gu et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Gu, Chang
Pan, Xufeng
Wang, Rui
Li, Yuan
Shen, Xuxia
Shi, Jianxin
Chen, Haiquan
Analysis of mutational and clinicopathologic characteristics of lung adenocarcinoma with clear cell component
title Analysis of mutational and clinicopathologic characteristics of lung adenocarcinoma with clear cell component
title_full Analysis of mutational and clinicopathologic characteristics of lung adenocarcinoma with clear cell component
title_fullStr Analysis of mutational and clinicopathologic characteristics of lung adenocarcinoma with clear cell component
title_full_unstemmed Analysis of mutational and clinicopathologic characteristics of lung adenocarcinoma with clear cell component
title_short Analysis of mutational and clinicopathologic characteristics of lung adenocarcinoma with clear cell component
title_sort analysis of mutational and clinicopathologic characteristics of lung adenocarcinoma with clear cell component
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029726/
https://www.ncbi.nlm.nih.gov/pubmed/27013585
http://dx.doi.org/10.18632/oncotarget.8258
work_keys_str_mv AT guchang analysisofmutationalandclinicopathologiccharacteristicsoflungadenocarcinomawithclearcellcomponent
AT panxufeng analysisofmutationalandclinicopathologiccharacteristicsoflungadenocarcinomawithclearcellcomponent
AT wangrui analysisofmutationalandclinicopathologiccharacteristicsoflungadenocarcinomawithclearcellcomponent
AT liyuan analysisofmutationalandclinicopathologiccharacteristicsoflungadenocarcinomawithclearcellcomponent
AT shenxuxia analysisofmutationalandclinicopathologiccharacteristicsoflungadenocarcinomawithclearcellcomponent
AT shijianxin analysisofmutationalandclinicopathologiccharacteristicsoflungadenocarcinomawithclearcellcomponent
AT chenhaiquan analysisofmutationalandclinicopathologiccharacteristicsoflungadenocarcinomawithclearcellcomponent